IMU
data caveat$52M5mo
Imugene
Biotech · Oncology
Clinical-stage immuno-oncology with multiple novel candidates
Data HealthTrials3 of 3 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$25.2M
Dec 2025 4C
Runway
5moCRITICAL
Based on Dec 2025 4C
Market Cap
$52M
Burn Rate
$16.0M/qtr
Dec 2025 4C
Shares Outstanding
360M
Pipeline Assets
4
Latest Insight(1)
19 Mar 2026Capital RaiseCleansing Notice
$6.4MPlacement·at$0.180·35.4M shares
3M Price
IMU.ASX$0.145-58.0% 3M
Low $0.135High $0.355
Pipeline Assets (4)
Azer-celSolid tumours
Phase 1CF33/VAXINIASolid tumours
Phase 1PD1-VaxxNSCLC
Phase 1HER-VaxxGastric cancer
Phase 2Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Capital Raises & Buybacks
1 raise
Current shares outstanding: 360M
Placement
2026-03-20placement
$6.4M
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-03-27 · 4-day lag
Short position
1.85%
arrow_drop_down-0.63% over 30 reports
Shares short
6.6M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
R&D Tax Incentive
$18.9M pending43.5% ATO refund
Adjusted Runwayincluding $18.9M pending RDTI
5 mo→8 mo(+3 mo)
FY2026estimated
Tracker estimate only — calculated as 43.5% of annualised R&D spend from last 4 quarters of 4C filings. Not AusIndustry-registered. Actual refund will depend on FY2026 eligible spend. Refund expected Oct–Dec 2026.
$18.92M
expected
How the R&D Tax Incentive works
Australian biotechs with < $20M aggregated turnover can claim a 43.5% refundable tax offseton eligible R&D expenditure each financial year (Jul–Jun). This is paid as a cash refund by the ATO — not a tax deduction — making it non-dilutive capital that directly extends cash runway.
Companies register eligible R&D activities with AusIndustry during the year, then lodge their tax return after 30 June. Refunds typically arrive October–Decemberof the same calendar year. For a company spending $5M/year on R&D, this is a ~$2.2M annual cash inflow.
Disclaimer: Amounts shown as estimated or are forward-looking estimates based on disclosed R&D expenditure and the 43.5% offset rate. Actual refunds may differ due to ATO assessments, eligibility rulings, or changes in R&D spend. This is not financial advice. Manually curated from 4C filings and company disclosures — verify independently.
Competitive Landscape
16 approved drugs1000 competitor trialsPhase 2+ · Non-ASX
Solid Tumours638 active trials
638 Ph1/PHASE2
Nsclc254 active trials
254 Ph1/PHASE2
Gastric Cancer108 active trials
108 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
3 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Mol Cancer Ther2025-09· PD1-Vaxx
J Immunother Cancer2025-08
Catalysts (10)· 6 upcoming · 4 past
Azer-cel Phase 1 dose escalation update
UpcomingExpectedarrow_upwardHigh15 May 2026
Azer-cel data presentation at ASCO 2026
UpcomingConfirmedarrow_upwardHigh30 May 2026
VAXINIA combination data ASCO 2026
UpcomingExpectedarrow_upwardHigh1 June 2026
Potential capital raise
UpcomingSpeculative
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High96/100
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
What drove these scores · rolling 2yr
arrow_drop_up
Stable burn rate — 11% quarterly variation — consistent spend
arrow_drop_up
Cash position improving — Cash balance grew over last 3 quarters
arrow_drop_up
R&D-focused spend — 86% of opex directed to R&D
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
★ RESULTS
Clinical Trials(7)
3 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 2066d
Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study
Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
18 Years+
Primary endpoint Frequency of Clinically Significant Clinical Events of Interest (CEI)
Ph1RecruitingEnrollment stale · 2599d
Azer-celFludarabineCyclophosphamide
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Non-Hodgkin Lymphoma · B-cell Acute Lymphoblastic Leukemia · Chronic Lymphocytic Leukemia +1 more
18 Years+
Primary endpoint Phase 1 Dose Escalation/Phase 1b Dose Expansion: Number of Participants with Azer-cel-related AEs Defined as Dose-limiting Toxicities (DLTs)
Ph1Active Not RecruitingEnrollment stale · 1647d
Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8 · Metastatic Triple-Negative Breast Carcinoma · Prognostic Stage IV Breast Cancer AJCC v8
18 Years+
Primary endpoint Incidence of adverse events